Your browser doesn't support javascript.
loading
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.
Issa, Ghayas C; Bidikian, Aram; Venugopal, Sangeetha; Konopleva, Marina; DiNardo, Courtney D; Kadia, Tapan M; Borthakur, Gautam; Jabbour, Elias; Pemmaraju, Naveen; Yilmaz, Musa; Short, Nicholas J; Maiti, Abhishek; Sasaki, Koji; Masarova, Lucia; Pierce, Sherry; Takahashi, Koichi; Tang, Guilin; Loghavi, Sanam; Patel, Keyur; Andreeff, Michael; Bhalla, Kapil; Garcia-Manero, Guillermo; Ravandi, Farhad; Kantarjian, Hagop; Daver, Naval.
Affiliation
  • Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Bidikian A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Venugopal S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Masarova L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Tang G; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Patel K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Bhalla K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Blood Adv ; 7(6): 933-942, 2023 03 28.
Article in En | MEDLINE | ID: mdl-36322818
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nuclear Proteins / Leukemia, Myeloid, Acute Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Blood Adv Year: 2023 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nuclear Proteins / Leukemia, Myeloid, Acute Type of study: Risk_factors_studies Limits: Humans Language: En Journal: Blood Adv Year: 2023 Document type: Article Country of publication: United States